Cell cycle and mitosis

Intuition [Beginner]

A cell's life revolves around one question: to divide or not to divide. The cell cycle is the sequence of events a cell goes through to grow and divide into two daughter cells. Every living organism depends on this process — a human body replaces roughly 50 billion cells per day through regulated division.

The cycle has four main phases. G1 (Gap 1): the cell grows and prepares for DNA replication. S (Synthesis): the cell copies its entire genome — all 3.2 billion base pairs in a human cell. G2 (Gap 2): the cell checks that DNA is fully and correctly copied, and prepares for division. M (Mitosis): the cell divides — the nucleus splits and then the cell pinches in two (cytokinesis).

Not all cells cycle continuously. Many cells exit the cycle into G0, a resting state where they neither divide nor prepare to divide. Nerve cells and cardiac muscle cells are permanently in G0. Liver cells can re-enter the cycle if the organ is damaged.

The cycle is controlled by checkpoints — quality-control stations that ensure each phase is completed correctly before the next begins. The three major checkpoints are: G1/S (is the cell big enough, are nutrients available, is DNA undamaged?), G2/M (is DNA fully copied and undamaged?), and the spindle checkpoint (are all chromosomes properly attached to the pulling apparatus before segregation?).

Visual [Beginner]

Imagine the cell cycle as a circular track with four stations. The cell starts at G1, moves to S, then G2, then M, and back to G1. At each station, a checkpoint inspector checks that everything is in order before allowing the cell to proceed.

During M phase (mitosis), the cell goes through a choreographed sequence: the chromosomes condense into tight X-shaped structures, line up in the middle of the cell, are pulled to opposite ends by protein cables, and then two new nuclei form around each set.

Worked example [Beginner]

A typical mammalian cell divides every 24 hours. S phase takes about 8 hours, G2 takes about 4 hours, and M phase takes about 1 hour. G1 takes the remaining 11 hours.

If a drug arrests cells at the G2/M checkpoint (preventing entry into mitosis), what fraction of an asynchronous population (cells randomly distributed throughout the cycle) would be arrested?

Cells in G1, S, and G2 are all upstream of the block and will accumulate at G2/M. Cells in M phase will complete division and re-enter G1, then progress through S and G2 before also being arrested. The fraction arrested at any instant is the fraction of cells in G1 + S + G2:

$(11+8+4)/24=23/24\approx 96\%$.

Nearly the entire population accumulates at G2/M, because only cells currently in M phase (1/24, about 4%) can complete the cycle. This is the principle behind cell synchronization by cell cycle blockers: treat a population with a drug that halts the cycle at one point, and virtually every cell ends up stopped there.

Check your understanding [Beginner]

Formal definition [Intermediate+]

The cell cycle is the ordered series of events by which a growing cell duplicates its contents and divides into two daughter cells. In eukaryotes, the cycle consists of four phases: G1, S, G2, and M.

Cyclins and CDKs

The engine of the cell cycle is the cyclin-dependent kinase (CDK) system. CDKs are serine/threonine kinases activated by binding cyclin partners. Cyclins are so named because their concentrations oscillate — they are synthesized and degraded at specific points in the cell cycle. A CDK without a bound cyclin is catalytically inert; cyclin binding opens the active-site cleft and allows substrate access.

Key cyclin-CDK complexes (mammalian):

Phase	Cyclin	CDK	Primary function
Late G1	Cyclin D (D1, D2, D3)	CDK4, CDK6	G1 progression, Rb phosphorylation
G1/S	Cyclin E (E1, E2)	CDK2	Initiation of S phase
S	Cyclin A	CDK2	DNA replication, S phase progression
G2/M	Cyclin A	CDK1	Preparation for mitosis
M	Cyclin B (B1, B2)	CDK1	Mitosis (MPF activity)

CDK regulation operates at four levels:

1. Cyclin binding. CDKs are inactive without cyclin binding. Cyclin binding opens the active site and correctly positions the catalytic residues.

2. Activating phosphorylation. T-loop phosphorylation (at Thr160 in CDK2) by CAK (CDK-activating kinase, itself composed of CDK7-cyclin H-MAT1) is required for full catalytic activity.

3. Inhibitory phosphorylation. Tyr15 and Thr14 phosphorylation by Wee1 and Myt1 kinases keeps CDK1-cyclin B inactive until the G2/M transition. Removal of these phosphates by Cdc25 phosphatases activates CDK1.

4. CDK inhibitors (CKIs). Two families: Cip/Kip proteins (p21/Cip1, p27/Kip1, p57/Kip2) inhibit cyclin E-CDK2 and cyclin A-CDK2; INK4 proteins (p16/INK4a, p15/INK4b) specifically inhibit CDK4 and CDK6.

5. Ubiquitin-mediated proteolysis. Cyclins are degraded by the 26S proteasome after ubiquitination by either the APC/C (anaphase-promoting complex/cyclosome, active from mid-M through G1) or SCF (Skp1-Cul1-F-box complex, active at G1/S). Cyclin destruction is the primary mechanism for dropping CDK activity and driving cycle transitions.

Checkpoints

G1/S checkpoint (Restriction point in mammals, Start in yeast). Checks cell size, nutrient availability, growth-factor signals, and DNA damage. Growth-factor signaling through RTK/MAPK 17.07.01 pending induces cyclin D expression. Cyclin D-CDK4/6 phosphorylates Rb. Hypophosphorylated Rb binds and inhibits E2F transcription factors. Progressive phosphorylation of Rb releases E2F, activating cyclin E, cyclin A, and DNA-replication genes. DNA damage activates ATM/ATR kinases, which stabilize p53, inducing p21 expression and inhibiting cyclin-CDK complexes to arrest the cell at G1/S.

G2/M checkpoint. Checks DNA replication completion and DNA damage. Inactive CDK1-cyclin B (inhibitory phosphates at Tyr15 from Wee1) is held in check. Cdc25 phosphatase removes the inhibitory phosphates, activating CDK1. Active CDK1 then phosphorylates and further activates Cdc25 (positive feedback) while inhibiting Wee1 (double-negative feedback), creating a bistable switch for irreversible mitotic entry.

Spindle assembly checkpoint (SAC). Checks that all kinetochores are properly attached to spindle microtubules. Unattached kinetochores recruit Mad2, which binds and inhibits Cdc20 (the APC/C activator). Without active APC/C-Cdc20, securin and cyclin B are not degraded. Securin inhibits separase, the protease that cleaves cohesin rings holding sister chromatids together.

Mitosis stages

1. Prophase: Chromosomes condense. Centrosomes duplicate and migrate to opposite poles. Spindle microtubules form.

2. Prometaphase: Nuclear envelope breaks down. Kinetochores capture spindle microtubules.

3. Metaphase: Chromosomes align at the metaphase plate. The SAC operates here.

4. Anaphase: Cohesin is cleaved by separase. Sister chromatids separate and move to opposite poles.

5. Telophase: Nuclear envelopes reform around each set of chromosomes. Chromosomes decondense.

Cytokinesis: A contractile ring of actin and myosin pinches the cell in two at the midbody. In animal cells, this creates two daughter cells. In plant cells, a cell plate forms instead.

Counterexamples to common slips

• Mitosis is the same as the cell cycle. Mitosis (M phase) is only about 1 hour of the ~24-hour mammalian cell cycle. Interphase (G1 + S + G2) occupies the remaining ~23 hours.

• CDKs are active throughout the cell cycle. Specific cyclin-CDK complexes are active only in specific phases: cyclin D-CDK4/6 in G1, cyclin E-CDK2 at G1/S, cyclin A-CDK2 in S, cyclin A-CDK1 in G2, cyclin B-CDK1 in M. The oscillation is the point.

• All cells divide continuously. Most cells in the adult body are in G0 (quiescent), including neurons and muscle cells. Only stem cells, progenitor cells, and activated immune cells cycle actively.

• The restriction point is a physical structure. It is a regulatory state — the point at which Rb becomes sufficiently hyperphosphorylated that E2F drives its own expression independently of growth-factor input.

Key theorem with proof [Intermediate+]

Theorem (Irreversible G1/S commitment via Rb-E2F positive feedback). Let $[E]$ denote the concentration of active (free) E2F transcription factor and $[R]$ the fraction of Rb in the hyperphosphorylated state. The mutual activation between E2F and cyclin E-CDK2, mediated by progressive Rb phosphorylation, creates a bistable switch: there exists a critical threshold $\theta$ such that if $[E]$ exceeds $\theta$, the positive feedback loop drives $[E]$ to its maximum even if the original growth-factor signal is withdrawn. The cell is committed to S phase.

Proof. The regulatory circuit couples three variables:

1. Active E2F ($E$) promotes transcription of cyclin E, so the cyclin E-CDK2 activity $C_E$ is an increasing function of $E$: $C_E=f_1(E)$, where $f_1$ is sigmoidal (transcriptional activation has a Hill-type dose-response).

2. Cyclin E-CDK2 phosphorylates Rb, converting Rb from the hypophosphorylated state (which binds and inhibits E2F) to the hyperphosphorylated state (which does not bind E2F). The fraction of hyperphosphorylated Rb satisfies $d[R_p]/dt=k_{\mathrm{phos}}{C}_E(1-[R_p])-k_{\mathrm{dephos}}[R_p]$, and at quasi-steady state $[R_p]=C_E/(C_E+K)$ where $K=k_{\mathrm{dephos}}/k_{\mathrm{phos}}$.

3. Free E2F concentration is the total E2F minus E2F bound to hypophosphorylated Rb. Since each hypophosphorylated Rb molecule binds one E2F, $E=E_{\mathrm{total}}-(1-[R_p])\cdot R_{\mathrm{total}}=E_{\mathrm{total}}-R_{\mathrm{total}}/(1+C_E/K)$.

Substituting $C_E=f_1(E)$ into the expression for $E$ gives a self-consistency equation: $E=E_{\mathrm{total}}-R_{\mathrm{total}}/(1+f_1(E)/K)$. The right-hand side is a saturating function of $E$ (increasing, sigmoidal), while the left-hand side is the identity line $y=E$. For appropriate parameters ($E_{\mathrm{total}}>R_{\mathrm{total}}$, Hill coefficient $\ge 2$ for $f_1$), these curves intersect at three points: a low-$E$ stable fixed point (G1 arrest), an unstable saddle point, and a high-$E$ stable fixed point (E2F fully active, S phase committed).

Growth factors shift the system by providing an initial phosphorylation of Rb through cyclin D-CDK4/6 (an input $I$ that increases $[R_p]$ independently of $E$). As $I$ increases, the low fixed point and the saddle point approach each other and annihilate in a saddle-node bifurcation, leaving only the high fixed point. The cell snaps to the high-E2F state.

This is irreversible with respect to the growth-factor input: once the saddle point is crossed, $C_E$ (driven by $E$) maintains Rb hyperphosphorylation independently of the original $I$. Removing growth factors drops $I$ to zero, but the system remains at the high fixed point because $C_E=f_1(E)$ is now self-sustaining. $\square$

Bridge. The Rb-E2F bistable switch builds toward 17.06.01 pending the DNA damage checkpoint, where p53-mediated p21 induction specifically prevents this switch from firing when DNA is compromised — and appears again in the mitotic-entry switch (CDK1-Cdc25-Wee1), which uses the same positive-feedback architecture at a different phase transition. The foundational reason both switches are bistable is that irreversible commitment protects against partial or reversible transitions that would leave the cell with broken chromosomes or incompletely replicated DNA. This is exactly the design principle that cancer cells subvert: the pattern recurs with Rb loss at G1/S, p53 mutation at G2/M, and SAC defects at metaphase. The bridge to oncology is that every approved CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) exploits the same bistability — by preventing the initial Rb phosphorylation, these drugs hold cells at the low-E2F fixed point even in the presence of growth-factor signals.

Exercises [Intermediate+]

Lean formalization [Intermediate+]

Mathlib does not cover cell-cycle regulatory networks, bistable switches arising from biochemical feedback, or the APC/C-mediated proteolysis cycle. The closest available infrastructure is the ODE existence/uniqueness layer (Mathlib.Analysis.ODE.PicardLindelof) and the dynamical-systems foundations in Mathlib.Analysis.ODE.Flow. Formalizing the Novak-Tyson cell-cycle model would require building a biochemical reaction-network ODE library on top of these, including mass-action kinetics, Hill functions, and Goldbeter-Koshland ultrasensitivity calculations — none of which exist. The checkpoint Boolean logic (SAC wait/don't-wait) would additionally require finite-state-machine or control-theoretic formalization. lean_status: none reflects these gaps.

Cyclin-CDK regulation and the restriction point [Master]

The restriction point, first identified by Pardee in 1974 ^{[Pardee 1974]}, is the critical G1 checkpoint at which a cell commits to division. Before the restriction point, the cell requires continuous growth-factor signaling to progress; after it, the cell proceeds through S, G2, and M even if growth factors are withdrawn. The molecular implementation of this commitment is the Rb-E2F axis.

The retinoblastoma protein (Rb) is a 110 kDa tumour suppressor that binds E2F-family transcription factors in its hypophosphorylated state, blocking their transactivation domain and recruiting chromatin-remodelling enzymes (histone deacetylases, SWI/SNF) that silence E2F target genes. E2F targets include cyclin E, cyclin A, DNA polymerase subunits, thymidine kinase, dihydrofolate reductase, and the MCM helicase components — essentially the entire S-phase programme.

Progressive Rb phosphorylation occurs through a two-step mechanism. First, growth-factor-activated cyclin D-CDK4/6 phosphorylates Rb at a subset of its 16 potential CDK phosphorylation sites (hypophosphorylation). This partially releases E2F, allowing low-level cyclin E transcription. Second, the newly synthesized cyclin E-CDK2 further phosphorylates Rb at the remaining sites (hyperphosphorylation), fully releasing E2F and creating a positive feedback loop: E2F activates cyclin E transcription, cyclin E-CDK2 hyperphosphorylates more Rb, releasing more E2F.

The cooperativity of this feedback is enhanced by a second positive loop: cyclin E-CDK2 phosphorylates and stabilizes cyclin E itself (by inhibiting its SCF-mediated ubiquitination), and E2F activates its own promoter through an upstream enhancer. These nested feedback loops sharpen the switch — once cyclin E-CDK2 activity crosses a critical threshold, Rb hyperphosphorylation becomes self-sustaining even if cyclin D-CDK4/6 activity drops to zero.

CDK4/6 inhibitors in cancer therapy. The clinical exploitation of this switch is one of the success stories of targeted cancer therapy. Three CDK4/6 inhibitors — palbociclib (Pfizer, FDA 2015), ribociclib (Novartis, FDA 2017), and abemaciclib (Eli Lilly, FDA 2017) — are approved for hormone-receptor-positive, HER2-negative advanced breast cancer. These ATP-competitive inhibitors block cyclin D-CDK4/6 activity, preventing Rb hypophosphorylation and holding cells at the low-E2F fixed point of the bistable switch. Tumours with functional Rb respond; tumours that have lost Rb (Rb-null) are resistant, because the switch has already been bypassed.

The CDK inhibitor proteins (CKIs) provide endogenous control over the restriction point. The INK4 family (p16/INK4a, p15/INK4b, p18/INK4c, p19/INK4d) specifically inhibit CDK4 and CDK6 by binding the CDK subunit and preventing cyclin D association. p16 is a critical tumour suppressor: it is deleted, silenced by promoter methylation, or mutated in a wide range of human cancers (pancreatic adenocarcinoma, glioblastoma, oesophageal squamous carcinoma). The Cip/Kip family (p21, p27, p57) has broader specificity, inhibiting cyclin E-CDK2 and cyclin A-CDK2; p21 is the primary effector of p53-mediated G1 arrest.

The Novak-Tyson mathematical model of the G1/S transition captures the restriction-point dynamics as a dynamical system with four core variables (cyclin D-CDK4/6, cyclin E-CDK2, E2F activity, and Rb phosphorylation state). Numerical simulation reproduces the observed all-or-none commitment behaviour: cells either arrest in G1 or commit fully to S phase, with no intermediate state. The saddle-node bifurcation in the model (at which the low-E2F fixed point disappears) corresponds to the experimentally observed restriction point.

DNA replication origin licensing and S-phase control [Master]

The cell must replicate its entire genome exactly once per cycle. Under-replication leaves daughter cells with missing genes; over-replication (rereplication) creates DNA breaks, amplifications, and genomic instability. The once-and-only-once mechanism that prevents rerelication was elucidated through a combination of genetics and biochemistry, with key contributions from Blow and Laskey 1988 ^{[Blow and Laskey 1988]} and Diffley and colleagues in the 1990s.

Origin licensing (G1 phase). Replication begins at discrete origins of replication. In budding yeast, these are defined ~100 bp autonomous replication sequence (ARS) elements; in metazoans, origins are less sequence-specific and more chromatin-context-dependent. The origin recognition complex (ORC, a six-subunit ATPase) binds origins throughout the cell cycle. During G1, when CDK activity is low, two licensing factors load onto ORC: Cdc6 (an AAA+ ATPase recruited by ORC) and Cdt1 (a protein that carries the MCM2-7 helicase complex to the origin). The MCM complex is loaded as an inactive double hexamer encircling double-stranded DNA. This loaded state is called the licensed or pre-replicative complex (pre-RC).

Origin firing (S phase). When S phase begins, CDK2-cyclin E and then CDK2-cyclin A activate the firing factors: DDK (Dbf4-dependent kinase, aka Cdc7-Dbf4) phosphorylates MCM subunits, while S-CDK phosphorylates Sld2 and Sld3 (in budding yeast; their metazoan functional analogues are RECQL4 and Treslin). These phosphorylation events recruit CDC45 and the GINS complex (Sld5-Psf1-Psf2-Psf3) to the MCM hexamer, converting it into the active CMG (Cdc45-MCM-GINS) helicase that unwinds DNA ahead of the replication fork. DNA polymerases alpha, delta, and epsilon are then recruited to synthesize the leading and lagging strands.

The once-and-only-once mechanism. The key insight is that licensing (pre-RC assembly) and firing (CMG activation) are mutually exclusive because both are controlled by CDK activity, but in opposite directions:

1. Licensing requires low CDK activity (G1 phase only). S-CDK and M-CDK both inhibit relicensing by: (a) phosphorylating and exporting Cdc6 from the nucleus; (b) phosphorylating Cdt1 and targeting it for SCF-mediated ubiquitination; (c) phosphorylating ORC subunits to reduce origin affinity; (d) in metazoans, activating the Cdt1 inhibitor geminin, which binds and sequesters Cdt1.

2. Firing requires high CDK activity (S phase).

Because CDK activity rises at the G1/S transition and stays high through S, G2, and M, origins can be licensed only in G1 (before CDK rises) and fired only in S/G2 (after CDK rises). Once an origin has fired, it cannot be relicensed because CDK remains high; this prevents rereplication within the same cycle. CDK is destroyed at mitotic exit (by APC/C-mediated cyclin degradation), resetting the system for the next G1 licensing window.

The replication checkpoint (ATR-Chk1). Not every fork proceeds smoothly. DNA damage, nucleotide depletion, or template secondary structures can stall replication forks. Stalled forks accumulate single-stranded DNA (ssDNA), which is coated by RPA (replication protein A). RPA-coated ssDNA recruits the kinase ATR (ataxia telangiectasia and Rad3-related), which — with its partner ATRIP — phosphorylates and activates the effector kinase Chk1. Chk1 stabilizes stalled forks (by inhibiting further origin firing and recruiting fork-stabilization factors), arrests the cell cycle (by inhibiting Cdc25, preventing CDK1 activation), and promotes repair. Loss of ATR or Chk1 causes fork collapse, double-strand breaks, and catastrophic genomic instability — the basis of the developmental disorder Seckel syndrome (ATR hypomorphism) and a therapeutic target in BRCA-deficient cancers (ATR inhibitors exploit synthetic lethality with homologous-recombination deficiency).

Mitosis — spindle assembly, SAC, and cytokinesis [Master]

Mitosis is the physical segregation of duplicated chromosomes into two daughter cells. The mitotic spindle — a bipolar array of microtubules nucleated from two centrosomes — captures chromosomes at their kinetochores and pulls sister chromatids to opposite poles. The entire process is monitored by the spindle assembly checkpoint (SAC), which prevents anaphase onset until every chromosome is bi-oriented (sister kinetochores attached to microtubules from opposite poles).

Centrosome duplication. The centrosome — the primary microtubule-organizing centre (MTOC) of animal cells — duplicates exactly once per cell cycle, in late G1/early S phase. Duplication is initiated by PLK4 (Polo-like kinase 4), which phosphorylates its substrate STIL, recruiting SAS-6 to form the cartwheel structure of the new centriole (procentriole). The procentriole elongates through S and G2, and the two centrosomes separate at G2/M to establish the bipolar spindle. PLK4 autoregulates its own levels through SCF-mediated degradation; PLK4 overexpression drives centrosome amplification (more than two centrosomes), a hallmark of many cancer cells that contributes to chromosome missegregation and aneuploidy.

Kinetochore-microtubule attachment. The kinetochore is a ~100-protein complex assembled on centromeric chromatin. The core microtubule-binding module is the Ndc80 complex (Ndc80-Nuf2-Spc24-Spc25), which binds the microtubule lattice with a high-affinity "toe-hold" that can maintain attachment even under the pulling forces generated during congression. Chromosomes initially captured by lateral attachments (microtubule wall contacts) are converted to end-on attachments (microtubule-plus-end contacts) through the coordinated action of the Aurora B kinase and the Ran-GTP gradient around chromosomes.

Aurora B is the central error-correction enzyme. It phosphorylates Ndc80 and other kinetochore substrates to destabilize incorrect attachments (syntelic: both sisters to the same pole; merotelic: one kinetochore attached to both poles). Correct amphitelic attachment (biorientation: each sister to the opposite pole) generates tension that physically separates Aurora B from its substrates at the outer kinetochore, allowing dephosphorylation and attachment stabilization. This tension-sensing mechanism was first proposed by Nicklas 1997 ^{[Nicklas 1997]} from micromanipulation experiments on grasshopper meiosis I chromosomes.

The spindle assembly checkpoint (SAC). The SAC prevents anaphase by inhibiting APC/C-Cdc20. Unattached kinetochores catalyse a conformational change in Mad2: closed Mad2 (C-Mad2) binds and inhibits Cdc20. The Mad1-Mad2 complex at unattached kinetochores acts as a template, converting soluble open Mad2 (O-Mad2) into C-Mad2, which then binds Cdc20. Additional checkpoint proteins (BubR1, Bub3) form the mitotic checkpoint complex (MCC = C-Mad2-Cdc20-BubR1-Bub3), which binds and directly inhibits APC/C.

The SAC operates as a sensitive AND gate: anaphase proceeds only when every kinetochore has been silenced (all have proper attachment). A single unattached kinetochore produces enough MCC to inhibit all cellular APC/C — the checkpoint signal is amplified far beyond the local kinetochore. Once the last kinetochore attaches, MCC production stops, existing MCC is disassembled by the AAA-ATPase p31(comet), and APC/C-Cdc20 is released to ubiquitinate securin and cyclin B.

Anaphase and cytokinesis. APC/C-Cdc20-mediated securin degradation releases separase, a cysteine protease that cleaves the cohesin subunit Rad21/Scc1 at the centromere and along chromosome arms. Cohesin cleavage dissolves the physical linkage between sister chromatids, allowing them to separate. Chromosome-to-pole movement (anaphase A) is driven by microtubule depolymerization at kinetochores and at poles; pole-to-pole separation (anaphase B) is driven by interpolar microtubule sliding (kinesin-5/Eg5 motors) and cortical pulling forces (dynein anchored at the cell cortex).

Cytokinesis begins with the positioning of the cleavage furrow. The central spindle (midzone) — a bundle of antiparallel microtubules between the separating chromosomes — recruits the centralspindlin complex (MKLP1 kinesin + MgcRacGAP), which activates the GTPase RhoA at the equatorial cortex. Active RhoA triggers actin nucleation through formins (mDia2) and myosin-II activation through ROCK-mediated phosphorylation of the myosin regulatory light chain. The resulting actomyosin contractile ring constricts, ingressing the plasma membrane inward. Final abscission — the severing of the intercellular bridge — is mediated by the ESCRT-III complex, which polymerizes into helical filaments at the midbody and catalyses membrane scission.

The cytoskeletal mechanisms underlying spindle assembly and the contractile ring are described in detail in 17.03.02 pending, which covers microtubule dynamics, kinetochore structure, and actomyosin contractility. The cell cycle regulates these cytoskeletal events through CDK-cyclin phosphorylation of microtubule-associated proteins and actin-binding proteins, ensuring that spindle assembly and contractile-ring formation occur at the correct cell-cycle stage.

Checkpoints, senescence, and cancer [Master]

The cell cycle checkpoints — G1/S, G2/M, and SAC — constitute a multi-layered surveillance system that maintains genomic integrity. When these checkpoints fail, the result is genomic instability, the enabling characteristic that allows tumours to acquire the mutations driving malignant progression. The connection between checkpoint failure and cancer is the central organising principle of tumour biology, formalised in Hanahan and Weinberg's "hallmarks of cancer" framework (2000, updated 2011) ^{[Hanahan and Weinberg 2000/2011]}.

The p53 pathway. The tumour suppressor p53 is activated by diverse stresses: DNA damage (double-strand breaks activate ATM, replication stress activates ATR), oncogene activation (via p19ARF in mouse, p14ARF in human), hypoxia, and telomere dysfunction. Activated p53 is a transcription factor that induces cell cycle arrest (through p21), apoptosis (through Bax, Puma, Noxa), or senescence (through p21 and p16), depending on the cell type, stress level, and cofactors present.

The p53-MDM2 negative feedback loop creates a tunable oscillator. MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. p53 transcriptionally activates MDM2, creating negative feedback: high p53 leads to high MDM2, which reduces p53. Under DNA damage, ATM/ATR phosphorylate both p53 (stabilizing it) and MDM2 (inhibiting it), breaking the loop and allowing p53 to accumulate. Mathematical modelling by Lahav and colleagues (2004) showed that this negative feedback can produce pulsatile p53 dynamics — individual cells exhibit discrete p53 pulses of fixed amplitude but variable number, with the number of pulses encoding the severity of DNA damage.

Oncogene-induced senescence (OIS). Paradoxically, activating an oncogene in a normal cell does not cause proliferation — it causes permanent cell cycle arrest. This was first demonstrated by Serrano et al. 1997 ^{[Serrano et al. 1997]}, who showed that expressing oncogenic Ras (G12V) in primary fibroblasts induces a senescence-like arrest rather than transformation. OIS is triggered by the hyperproliferative signal from the oncogene activating the DNA damage response (through replication stress from unscheduled S-phase entry) and the p16/Rb pathway. OIS functions as a tumour-suppressive barrier: benign lesions (nevi, colonic adenomas, pancreatic PanIN) are senescent and stable; malignant progression requires inactivation of the senescence machinery (p53 loss, p16 loss, or Rb loss).

Telomere crisis and reactivation. Somatic cells have a finite replicative lifespan (the Hayflick limit), determined by telomere length. Telomeres — the TTAGGG-repeat caps at chromosome ends — shorten by ~50-100 bp per division because DNA polymerase cannot fully replicate the 3' end (the end-replication problem, first described by Olovnikov 1971 and Watson 1972). When telomeres become critically short, they lose their protective t-loop structure and are sensed as DNA double-strand breaks, activating p53 and triggering replicative senescence (the M1 stage).

Cells that bypass M1 (e.g., through p53 loss) continue dividing until telomeres become so short that end-to-end fusions occur, producing dicentric chromosomes that break during mitosis — a catastrophic period called crisis (the M2 stage). Most cells in crisis die. Rare survivors reactivate telomerase (the ribonucleoprotein reverse transcriptase TERT, normally silenced in somatic cells) or activate alternative lengthening of telomeres (ALT, a recombination-based mechanism). Telomerase reactivation is found in ~90% of human cancers and is one of the most specific cancer biomarkers.

Multi-stage carcinogenesis. The age-incidence relationship of most human cancers follows a power law: $\log (\text{incidence rate})\approx n\cdot \log (\text{age})-C$, where $n\approx 5$–6 for epithelial cancers. This relationship was explained by Armitage and Doll 1954 ^{[Armitage and Doll 1954]} as implying that 5–7 independent mutational events (each with roughly constant probability per year) must accumulate in a single cell lineage before a clinically detectable tumour results. Each "hit" corresponds to the inactivation of a tumour-suppressor pathway or the activation of an oncogenic pathway, many of which directly disrupt cell-cycle checkpoints:

• Hit 1: Loss of p16 (INK4a) → unchecked cyclin D-CDK4/6 → Rb hyperphosphorylation → G1/S checkpoint bypass.
• Hit 2: Loss of p53 → no G1/S or G2/M DNA damage arrest, no apoptosis → mutation accumulation.
• Hit 3: Cyclin D amplification or Ras activation → constitutive proliferative signaling.
• Hit 4: Telomerase reactivation → replicative immortality.
• Hit 5: Loss of SAC components → chromosomal instability (CIN) → fuel for further adaptation.

The cell cycle, viewed from this perspective, is the central battlefield of carcinogenesis: every gate (restriction point, G2/M, SAC) is a tumour-suppressive barrier, and cancer evolves by progressively dismantling each one.

Synthesis. The foundational reason the cell cycle is reliable enough to support multicellular life is that every phase transition is guarded by a bistable switch backed by checkpoint surveillance. The central insight is that cyclin-CDK complexes, APC/C-mediated proteolysis, and checkpoint kinases form interlocking feedback loops that make each transition irreversible — putting these together with the Rb/E2F commitment switch at G1/S, the CDK1/Cdc25 mitotic-entry switch at G2/M, and the SAC anaphase gate at metaphase gives a three-layer architecture of irreversible commitment. This is exactly the structure that identifies cell cycle control with nonlinear dynamical systems 02.12.01: bistability from positive feedback, oscillations from negative feedback through the APC/C, and checkpoint enforcement as bifurcation control. The bridge to cancer biology is that oncogenic mutations systematically dismantle these switches — the pattern recurs across the G1/S restriction point (Rb loss), the G2/M gate (p53 mutation), and the SAC (chromosomal instability). The dynamical-systems perspective generalises: the Novak-Tyson ODE models of the full cycle reproduce not just the transitions but the timing, the hysteresis, and the response to perturbations, identifying the cell cycle as a limit-cycle oscillator 02.12.14 whose period and amplitude are set by the kinetic parameters of cyclin synthesis and degradation.

Connections [Master]

• DNA replication 17.05.01 pending. The DNA replication machinery described in 17.05.01 pending — DNA polymerases, the MCM helicase, the replication fork — is activated during S phase by the cyclin-CDK system detailed here. The once-and-only-once licensing mechanism that prevents rereplication operates through CDK-dependent inhibition of relicensing factors, directly linking cell-cycle control to the replication apparatus. The G2/M checkpoint enforces the dependency that replication must complete before mitosis begins.

• Cell signaling 17.07.01 pending. The G1/S restriction point integrates extracellular growth-factor signals (EGF, PDGF, FGF, insulin) transmitted through the RTK-MAPK pathway 17.07.01 pending into the cyclin D-CDK4/6 module. Without growth-factor signaling, cyclin D is not transcribed, Rb remains hypophosphorylated, and the cell stays in G1. The connection runs both ways: CDK activity feeds back on signaling pathways through phosphorylation of signaling intermediates.

• Mutation and repair 17.06.01 pending. The DNA damage checkpoints (G1/S and G2/M) directly consume the repair machinery described in 17.06.01 pending. ATM and ATR kinases, activated by double-strand breaks and replication stress respectively, halt the cell cycle via p53/p21 (G1 arrest) and Chk1/Cdc25 inhibition (G2 arrest) to allow repair before replication or division proceeds. Failure of these checkpoints — the hallmark of p53-mutant cancers — allows cells to replicate and segregate damaged DNA, accelerating the mutation accumulation described in 17.06.01 pending.

• Cytoskeleton and contractile proteins 17.03.02 pending. Mitotic spindle assembly, kinetochore-microtubule attachment, anaphase chromosome segregation, and cytokinetic ring constriction are all cytoskeletal processes whose molecular mechanisms are detailed in 17.03.02 pending. The cell cycle regulates these events through CDK-cyclin phosphorylation of microtubule-associated proteins and actin-binding proteins.

• Dynamical systems theory 02.12.01. The cell cycle is a limit-cycle oscillator in the dynamical-systems sense, with the CDK-cyclin network producing sustained oscillations in kinase activity. The bistable switches at G1/S and G2/M are saddle-node bifurcations; the APC/C negative feedback creates the oscillation. The Novak-Tyson models are systems of ODEs whose analysis uses the same tools covered in 02.12.01.

• Resting potential and ion channels 17.09.01 (pending). Cell cycle progression in electrically excitable cells (neurons, cardiomyocytes) is modulated by membrane potential: depolarisation promotes proliferation in some contexts (neural progenitor cells), while hyperpolarisation is associated with cell cycle exit. The CDK-cyclin machinery described here and the ion-channel biophysics of 17.09.01 intersect in stem-cell biology and cancer electrophysiology.

• Mendelian genetics 19.01.01 pending. Mendel's law of segregation is the macroscopic consequence of homologous chromosome separation at anaphase I of meiosis; independent assortment reflects random orientation of different chromosome pairs on the meiotic spindle. The cell division mechanics described here are the physical substrate of Mendelian inheritance: recombination at prophase I produces the non-parental gamete types that make linkage detectable.

Historical & philosophical context [Master]

The cell cycle was first defined as a sequence of discrete phases by Howard and Pelc in 1953 ^{[Howard and Pelc 1953]}, who used radioisotope labelling of DNA in bean root tips to demonstrate that DNA synthesis occurs in a defined interval (S phase) separated from mitosis by two gap phases (G1 and G2). This four-phase framework immediately raised the question of what drives the transitions between phases — a question that took three decades to answer at the molecular level.

The genetic dissection of the cell cycle began with Leland Hartwell's isolation of cdc (cell division cycle) mutants in budding yeast (Saccharomyces cerevisiae) in the early 1970s ^{[Hartwell et al. 1974]}. Hartwell's key insight was that temperature-sensitive cdc mutants arrested at a specific point in the cycle when shifted to the restrictive temperature, allowing the ordering of gene functions along the cycle. Paul Nurse found the homologous gene (cdc2) in fission yeast (Schizosaccharomyces pombe) and demonstrated that the human version (CDK1) could substitute for the yeast gene — establishing the universal conservation of the CDK-cyclin cell-cycle engine across all eukaryotes ^{[Nurse 1975]}. Tim Hunt discovered cyclins in sea urchin (Arbacia punctulata) embryos as proteins that accumulated during interphase and abruptly disappeared at each cleavage division ^{[Hunt et al. 1982]}. The convergence — CDKs require cyclins, cyclins oscillate, CDK-cyclin complexes drive phase transitions — was the molecular synthesis that earned Hartwell, Nurse, and Hunt the 2001 Nobel Prize in Physiology or Medicine.

The bistable-switch and checkpoint concepts were developed by Hartwell and Weinert (1989), who proposed that the cell cycle contains surveillance mechanisms (checkpoints) that ensure the correct order of events. The mathematical formalization of the cell cycle as a dynamical system was developed by Novak and Tyson in a series of papers from 1993 onward ^{[Novak and Tyson 1993]}, who showed that the CDK-cyclin regulatory network, modelled as a system of ODEs, produces limit-cycle oscillations with bistable transitions. Their models reproduce the major features of the cell cycle and make testable predictions about how perturbations (drug treatments, mutations) affect cycle timing.

Bibliography [Master]

@article{HowardPelc1953,
  author = {Howard, A. and Pelc, S. R.},
  title = {Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage},
  journal = {Heredity},
  volume = {6},
  year = {1953},
  pages = {261-273},
}

@article{Hartwell1974,
  author = {Hartwell, L. H. and Culotti, J. and Pringle, J. R. and Reid, B. J.},
  title = {Genetic control of the cell division cycle in yeast},
  journal = {Science},
  volume = {183},
  year = {1974},
  pages = {46-51},
}

@article{Nurse1975,
  author = {Nurse, P.},
  title = {Genetic control of cell size at cell division in yeast},
  journal = {Nature},
  volume = {256},
  year = {1975},
  pages = {547-551},
}

@article{Hunt1982,
  author = {Evans, T. and Rosenthal, E. T. and Youngblom, J. and Distel, D. and Hunt, T.},
  title = {Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division},
  journal = {Cell},
  volume = {33},
  year = {1983},
  pages = {389-396},
}

@article{Pardee1974,
  author = {Pardee, A. B.},
  title = {A restriction point for control of normal animal cell proliferation},
  journal = {Proc. Natl. Acad. Sci. USA},
  volume = {71},
  year = {1974},
  pages = {1286-1290},
}

@article{NovakTyson1993,
  author = {Novak, B. and Tyson, J. J.},
  title = {Numerical analysis of a comprehensive model of {M}-phase control in {Xenopus} oocyte extracts and intact embryos},
  journal = {J. Cell Sci.},
  volume = {106},
  year = {1993},
  pages = {1153-1168},
}

@article{BlowLaskey1988,
  author = {Blow, J. J. and Laskey, R. A.},
  title = {A role for the nuclear envelope in controlling {DNA} replication within the cell cycle},
  journal = {Nature},
  volume = {332},
  year = {1988},
  pages = {546-548},
}

@article{Serrano1997,
  author = {Serrano, M. and Lin, A. W. and McCurrach, M. E. and Beach, D. and Lowe, S. W.},
  title = {Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16{INK4a}},
  journal = {Cell},
  volume = {88},
  year = {1997},
  pages = {593-602},
}

@article{ArmitageDoll1954,
  author = {Armitage, P. and Doll, R.},
  title = {The age distribution of cancer and a multi-stage theory of carcinogenesis},
  journal = {Br. J. Cancer},
  volume = {8},
  year = {1954},
  pages = {1-12},
}

@article{HanahanWeinberg2000,
  author = {Hanahan, D. and Weinberg, R. A.},
  title = {The hallmarks of cancer},
  journal = {Cell},
  volume = {100},
  year = {2000},
  pages = {57-70},
}

@article{HanahanWeinberg2011,
  author = {Hanahan, D. and Weinberg, R. A.},
  title = {Hallmarks of cancer: the next generation},
  journal = {Cell},
  volume = {144},
  year = {2011},
  pages = {646-674},
}

@article{MasuiMarkert1971,
  author = {Masui, Y. and Markert, C. L.},
  title = {Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes},
  journal = {J. Exp. Zool.},
  volume = {177},
  year = {1971},
  pages = {129-145},
}

@article{WeinertHartwell1989,
  author = {Weinert, T. and Hartwell, L. H.},
  title = {Control of {G2} delay by the rad9 gene of {Saccharomyces cerevisiae}},
  journal = {J. Cell Sci.},
  volume = {12},
  year = {1989},
  pages = {165-168},
}

@book{Morgan2007,
  author = {Morgan, D. O.},
  title = {The Cell Cycle: Principles of Control},
  publisher = {New Science Press},
  year = {2007},
}

@book{Alberts2014,
  author = {Alberts, B. and Johnson, A. and Lewis, J. and Morgan, D. and Raff, M. and Roberts, K. and Walter, P.},
  title = {Molecular Biology of the Cell},
  publisher = {Garland Science},
  year = {2014},
  edition = {6th},
}